'Enhanced Brain Function' Supplement Sales Only A Memory After NAD Review
This article was originally published in The Rose Sheet
Council of Better Business Bureau's industry self-regulation arm says UltraMax Health, after previously not responding to a request for evidence supporting Max Synapse online ad claims, stated in writing that it stopped using the claims and no longer is selling the product.
You may also be interested in...
Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
Vaya marketed Vayarin supplement in the US, but its parent firm, specialty chemicals company Enzymotec, responds to NAD request for substantiation by saying that it changed "its strategy to focus on serving as an ingredient-supplier rather than engaging in the sale of consumer products." Change includes closing Vaya and ceasing Vayarin sales in the US.
NAD refers UltraMax Health's supplement claim to the FTC after it fails to provide substantiation. CRN emphasizes claims alone are not the problem, but the firm's failure to provide substantiation.